Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 381

1.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group.

N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1. Erratum in: N Engl J Med. 2013 Jun 20;368(25):2442.

PMID:
23020162
[PubMed - indexed for MEDLINE]
Free Article
2.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.

J Clin Oncol. 2012 Sep 10;30(26):3234-41. doi: 10.1200/JCO.2011.40.5902. Epub 2012 May 29.

PMID:
22649126
[PubMed - indexed for MEDLINE]
Free Article
3.

Patient-reported outcomes from EMILIA, a randomized phase 3 study of trastuzumab emtansine (T-DM1) versus capecitabine and lapatinib in human epidermal growth factor receptor 2-positive locally advanced or metastatic breast cancer.

Welslau M, Diéras V, Sohn JH, Hurvitz SA, Lalla D, Fang L, Althaus B, Guardino E, Miles D.

Cancer. 2014 Mar 1;120(5):642-51. doi: 10.1002/cncr.28465. Epub 2013 Nov 12.

PMID:
24222194
[PubMed - indexed for MEDLINE]
4.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H; TH3RESA study collaborators.

Lancet Oncol. 2014 Jun;15(7):689-99. doi: 10.1016/S1470-2045(14)70178-0. Epub 2014 May 2.

PMID:
24793816
[PubMed - indexed for MEDLINE]
5.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA.

J Clin Oncol. 2013 Mar 20;31(9):1157-63. doi: 10.1200/JCO.2012.44.9694. Epub 2013 Feb 4. Erratum in: J Clin Oncol. 2013 Aug 10;31(23):2977.

PMID:
23382472
[PubMed - indexed for MEDLINE]
Free Article
6.

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.

Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K.

Curr Med Res Opin. 2013 Apr;29(4):405-14. doi: 10.1185/03007995.2013.775113. Epub 2013 Mar 1. Review.

PMID:
23402224
[PubMed - indexed for MEDLINE]
7.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.

J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865. Epub 2010 Dec 20.

PMID:
21172893
[PubMed - indexed for MEDLINE]
Free Article
8.

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

Baselga J, Cortés J, Kim SB, Im SA, Hegg R, Im YH, Roman L, Pedrini JL, Pienkowski T, Knott A, Clark E, Benyunes MC, Ross G, Swain SM; CLEOPATRA Study Group.

N Engl J Med. 2012 Jan 12;366(2):109-19. doi: 10.1056/NEJMoa1113216. Epub 2011 Dec 7.

PMID:
22149875
[PubMed - indexed for MEDLINE]
Free Article
9.

Exposure-response relationship of T-DM1: insight into dose optimization for patients with HER2-positive metastatic breast cancer.

Wang J, Song P, Schrieber S, Liu Q, Xu Q, Blumenthal G, Amiri Kordestani L, Cortazar P, Ibrahim A, Justice R, Wang Y, Tang S, Booth B, Mehrotra N, Rahman A.

Clin Pharmacol Ther. 2014 May;95(5):558-64. doi: 10.1038/clpt.2014.24. Epub 2014 Jan 31.

PMID:
24488143
[PubMed - indexed for MEDLINE]
10.

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.

Krop I, Winer EP.

Clin Cancer Res. 2014 Jan 1;20(1):15-20. doi: 10.1158/1078-0432.CCR-13-0541. Epub 2013 Oct 17.

PMID:
24135146
[PubMed - indexed for MEDLINE]
11.

A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses.

Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello-Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE.

Breast Cancer Res Treat. 2008 Dec;112(3):533-43. doi: 10.1007/s10549-007-9885-0. Epub 2008 Jan 11.

PMID:
18188694
[PubMed - indexed for MEDLINE]
12.

A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

Martin M, Bonneterre J, Geyer CE Jr, Ito Y, Ro J, Lang I, Kim SB, Germa C, Vermette J, Wang K, Wang K, Awada A.

Eur J Cancer. 2013 Dec;49(18):3763-72. doi: 10.1016/j.ejca.2013.07.142. Epub 2013 Aug 15.

PMID:
23953056
[PubMed - indexed for MEDLINE]
13.

Lapatinib for the treatment of HER2-overexpressing breast cancer.

Jones J, Takeda A, Picot J, von Keyserlingk C, Clegg A.

Health Technol Assess. 2009 Oct;13 Suppl 3:1-6. doi: 10.3310/hta13suppl3/01. Review.

PMID:
19846022
[PubMed - indexed for MEDLINE]
Free Article
14.

Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

Geyer CE, Forster J, Lindquist D, Chan S, Romieu CG, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, Skarlos D, Campone M, Davidson N, Berger M, Oliva C, Rubin SD, Stein S, Cameron D.

N Engl J Med. 2006 Dec 28;355(26):2733-43. Erratum in: N Engl J Med. 2007 Apr 5;356(14):1487.

PMID:
17192538
[PubMed - indexed for MEDLINE]
Free Article
15.

[Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].

Gonçalves A, Trédan O, Villanueva C, Dumontet C.

Bull Cancer. 2012 Dec;99(12):1183-91. doi: 10.1684/bdc.2012.1669. Review. French.

PMID:
23247898
[PubMed - indexed for MEDLINE]
16.

Trastuzumab-DM1: a clinical update of the novel antibody-drug conjugate for HER2-overexpressing breast cancer.

Barginear MF, John V, Budman DR.

Mol Med. 2013 Jan 22;18:1473-9. doi: 10.2119/molmed.2012.00302.

PMID:
23196784
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.

LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX.

Clin Cancer Res. 2011 Oct 15;17(20):6437-47. doi: 10.1158/1078-0432.CCR-11-0762. Review.

PMID:
22003071
[PubMed - indexed for MEDLINE]
Free Article
18.

Phase IIa trial of trastuzumab emtansine with pertuzumab for patients with human epidermal growth factor receptor 2-positive, locally advanced, or metastatic breast cancer.

Miller KD, Diéras V, Harbeck N, Andre F, Mahtani RL, Gianni L, Albain KS, Crivellari D, Fang L, Michelson G, de Haas SL, Burris HA.

J Clin Oncol. 2014 May 10;32(14):1437-44. doi: 10.1200/JCO.2013.52.6590. Epub 2014 Apr 14.

PMID:
24733796
[PubMed - indexed for MEDLINE]
19.

Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.

Gajria D, Gonzalez J, Feigin K, Patil S, Chen C, Theodoulou M, Drullinsky P, D'Andrea G, Lake D, Norton L, Hudis CA, Traina TA.

Breast Cancer Res Treat. 2012 Jan;131(1):111-6. doi: 10.1007/s10549-011-1749-y. Epub 2011 Sep 4.

PMID:
21898114
[PubMed - indexed for MEDLINE]
20.

Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.

Haddley K.

Drugs Today (Barc). 2013 Nov;49(11):701-15. doi: 10.1358/dot.2013.49.11.2020937. Review.

PMID:
24308017
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk